Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 944, doi. 10.1111/dom.16094
- By:
- Publication type:
- Article
Works matching AU Triplitt, Curtis
Results: 68
1
2
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 1033, doi. 10.1111/dom.15404
- By:
- Publication type:
- Article
3
Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 417, doi. 10.1111/dom.15327
- By:
- Publication type:
- Article
4
Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1810, doi. 10.1111/dom.14767
- By:
- Publication type:
- Article
5
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 899, doi. 10.1111/dom.14650
- By:
- Publication type:
- Article
6
Insulin secretion is a strong predictor for need of insulin therapy in patients with new‐onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1631, doi. 10.1111/dom.14383
- By:
- Publication type:
- Article
7
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
- Published in:
- 2010
- By:
- Publication type:
- journal article
8
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
- Published in:
- Vascular Health & Risk Management, 2010, v. 6, p. 671
- By:
- Publication type:
- Article
9
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists.
- Published in:
- American Journal of Health-System Pharmacy, 2021, v. 78, n. 7, p. 556, doi. 10.1093/ajhp/zxaa413
- By:
- Publication type:
- Article
10
Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus.
- Published in:
- Pharmacotherapy, 2006, v. 26, n. 3, p. 360, doi. 10.1592/phco.26.3.360
- By:
- Publication type:
- Article
11
Exenatide: A Viewpoint by Curtis Triplitt and Ralph A. DeFronzo.
- Published in:
- Drugs, 2005, v. 65, n. 12, p. 1693, doi. 10.2165/00003495-200565120-00009
- By:
- Publication type:
- Article
12
Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation.
- Published in:
- Physiological Reports, 2014, v. 2, n. 8, p. n/a, doi. 10.14814/phy2.12123
- By:
- Publication type:
- Article
13
Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 6, p. 554, doi. 10.1177/10600280241287790
- By:
- Publication type:
- Article
14
Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 1, p. 161, doi. 10.1210/clinem/dgad438
- By:
- Publication type:
- Article
15
Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.
- Published in:
- 2020
- By:
- Publication type:
- journal article
16
Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients.
- Published in:
- Brazilian Journal of Nephrology / Jornal Brasileiro de Nefrologia, 2014, v. 36, n. 1, p. 80, doi. 10.5935/0101-2800.20140014
- By:
- Publication type:
- Article
17
A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement.
- Published in:
- Diabetes Spectrum, 2022, v. 35, n. 3, p. 320, doi. 10.2337/ds22-0041
- By:
- Publication type:
- Article
18
Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes.
- Published in:
- Diabetes Spectrum, 2021, v. 34, n. 3, p. 248, doi. 10.2337/ds20-0067
- By:
- Publication type:
- Article
19
Improving Outcomes of People With Diabetes Through Overcoming Therapeutic Inertia.
- Published in:
- Diabetes Spectrum, 2020, v. 33, n. 1, p. 5, doi. 10.2337/ds19-0067
- By:
- Publication type:
- Article
20
Oh, What Times We Live In!
- Published in:
- 2019
- By:
- Publication type:
- Editorial
21
Novel Agents for the Treatment of Type 2 Diabetes.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
22
Novel Agents for the Treatment of Type 2 Diabetes.
- Published in:
- Diabetes Spectrum, 2014, v. 27, n. 2, p. 100, doi. 10.2337/diaspect.27.2.100
- By:
- Publication type:
- Article
23
Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes.
- Published in:
- Diabetes Spectrum, 2008, v. 21, n. 3, p. 177, doi. 10.2337/diaspect.21.3.177
- By:
- Publication type:
- Article
24
Drug Interactions of Medications Commonly Used in Diabetes.
- Published in:
- Diabetes Spectrum, 2006, v. 19, n. 4, p. 202, doi. 10.2337/diaspect.19.4.202
- By:
- Publication type:
- Article
25
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus.
- Published in:
- Expert Review of Endocrinology & Metabolism, 2006, v. 1, n. 3, p. 329, doi. 10.1586/17446651.1.3.329
- By:
- Publication type:
- Article
26
A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement.
- Published in:
- Diabetes Care, 2022, v. 45, n. 8, p. 1707, doi. 10.2337/dc22-en08
- By:
- Publication type:
- Article
27
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
- Published in:
- Diabetes Care, 2022, v. 45, n. 6, p. 1372, doi. 10.2337/dc21-1798
- By:
- Publication type:
- Article
28
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.
- Published in:
- 2021
- By:
- Publication type:
- journal article
29
Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
- Published in:
- 2020
- By:
- Publication type:
- journal article
30
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 Diabetes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
31
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
- Published in:
- 2020
- By:
- Publication type:
- journal article
32
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331.
- Published in:
- 2017
- By:
- Publication type:
- journal article
33
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
34
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
- Published in:
- 2013
- By:
- Publication type:
- journal article
35
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 9, p. 2756, doi. 10.2337/dc12-2072
- By:
- Publication type:
- Article
36
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
- Published in:
- 2010
- By:
- Publication type:
- journal article
37
Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin.
- Published in:
- Diabetes Care, 2010, v. 33, n. 5, p. 951, doi. 10.2337/dc09-1521
- By:
- Publication type:
- Article
38
Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms.
- Published in:
- Diabetes Care, 2008, v. 31, n. 1, p. 121, doi. 10.2337/dc07-0711
- By:
- Publication type:
- Article
39
Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea.
- Published in:
- Diabetes Care, 2006, v. 29, n. 11, p. 2371, doi. 10.2337/dc06-0564
- By:
- Publication type:
- Article
40
Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.
- Published in:
- 2004
- By:
- Publication type:
- journal article
41
Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
- Published in:
- Clinical Diabetes, 2024, v. 42, n. 1, p. 74, doi. 10.2337/cd22-0118
- By:
- Publication type:
- Article
42
A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
43
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
- Published in:
- Clinical Diabetes, 2017, v. 35, n. 4, p. 209, doi. 10.2337/cd16-0072
- By:
- Publication type:
- Article
44
Nephropathy in Youth and Young Adults with Type 2 Diabetes.
- Published in:
- Current Diabetes Reports, 2014, v. 14, n. 2, p. 1, doi. 10.1007/s11892-013-0456-y
- By:
- Publication type:
- Article
45
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes.
- Published in:
- Diabetes, 2025, v. 74, n. 1, p. 43, doi. 10.2337/db24-0406
- By:
- Publication type:
- Article
46
A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
47
756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-756-P
- By:
- Publication type:
- Article
48
352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-352-OR
- By:
- Publication type:
- Article
49
1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1136-P
- By:
- Publication type:
- Article
50
1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1070-P
- By:
- Publication type:
- Article